Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells.

Adenoviral vectors based on adenovirus type 35 (rAd35) have the advantage of low natural vector immunity and induce strong, insert-specific T- and B-cell responses, making them prime-candidate vaccine carriers. However, severe vector-genome instability of E1-deleted rAd35 vectors was observed, hampering universal use. The instability of E1-deleted rAd35 vector proved to be caused by low pIX expression induced by removal of the pIX promoter, which was located in the E1B region of B-group viruses. Reinsertion of a minimal pIX promoter resulted in stable vectors able to harbour large DNA inserts (> 5 kb). In addition, it is shown that replacement of the E4-Orf6 region of Ad35 by the E4-Orf6 region of Ad5 resulted in successful propagation of an E1-deleted rAd35 vector on existing E1-complementing cell lines, such as PER.C6 cells. The ability to produce these carriers on PER.C6 contributes significantly to the scale of manufacturing of rAd35-based vaccines. Next, a stable rAd35 vaccine was generated carrying Mycobacterium tuberculosis antigens Ag85A, Ag85B and TB10.4. The antigens were fused directly, resulting in expression of a single polyprotein. This vaccine induced dose-dependent CD4+ and CD8+ T-cell responses against multiple antigens in mice. It is concluded that the described improvements to the rAd35 vector contribute significantly to the further development of rAd35 carriers for mass-vaccination programmes for diseases such as tuberculosis, AIDS and malaria.

[1]  B. Berkhout,et al.  Immunogenicity and Protection of a Recombinant Human Adenovirus Serotype 35-Based Malaria Vaccine against Plasmodium yoelii in Mice , 2006, Infection and Immunity.

[2]  M. Lifton,et al.  Immunogenicity of Heterologous Prime-Boost Regimens Involving Recombinant Adenovirus Serotype 11 (Ad11) and Ad35 Vaccine Vectors in the Presence of Anti-Ad5 Immunity , 2005, Journal of Virology.

[3]  G. Nabel,et al.  Enhanced Breadth of CD4 T-Cell Immunity by DNA Prime and Adenovirus Boost Immunization to Human Immunodeficiency Virus Env and Gag Immunogens , 2005, Journal of Virology.

[4]  B. Walker,et al.  Neutralizing Antibodies to Adenovirus Serotype 5 Vaccine Vectors Are Directed Primarily against the Adenovirus Hexon Protein1 , 2005, The Journal of Immunology.

[5]  Wenlin Huang,et al.  Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats , 2005, Virus Research.

[6]  G. Nabel,et al.  Adenovirus vector-based vaccines for human immunodeficiency virus type 1. , 2005, Human gene therapy.

[7]  J. Mascola,et al.  Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys , 2005, Journal of Virology.

[8]  A. Bennett,et al.  Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus. , 2005, Vaccine.

[9]  B. Berkhout,et al.  Novel Replication-Incompetent Vector Derived from Adenovirus Type 11 (Ad11) for Vaccination and Gene Therapy: Low Seroprevalence and Non-Cross-Reactivity with Ad5 , 2004, Journal of Virology.

[10]  B. Berkhout,et al.  Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector , 2004, AIDS.

[11]  S. Kostense,et al.  Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity1 , 2004, The Journal of Immunology.

[12]  R. Parks,et al.  Activation of Adenoviral Gene Expression by Protein IX Is Not Required for Efficient Virus Replication , 2004, Journal of Virology.

[13]  J. Shiver,et al.  Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. , 2004, Annual review of medicine.

[14]  H. Ertl,et al.  Induction of CD8+ T Cells to an HIV-1 Antigen through a Prime Boost Regimen with Heterologous E1-Deleted Adenoviral Vaccine Carriers 1 , 2003, The Journal of Immunology.

[15]  S. Swaminathan,et al.  Replication-Defective Adenoviral Vaccine Vector for the Induction of Immune Responses to Dengue Virus Type 2 , 2003, Journal of Virology.

[16]  R. Crystal,et al.  Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen. , 2003, Human gene therapy.

[17]  C. Kedinger,et al.  Adenovirus protein IX sequesters host‐cell promyelocytic leukaemia protein and contributes to efficient viral proliferation , 2003, EMBO reports.

[18]  S. Santra,et al.  Plasmid Chemokines and Colony-Stimulating Factors Enhance the Immunogenicity of DNA Priming-Viral Vector Boosting Human Immunodeficiency Virus Type 1 Vaccines , 2003, Journal of Virology.

[19]  R. Koup,et al.  Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates , 2003, Nature.

[20]  S. Kostense,et al.  Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity , 2003, Journal of Virology.

[21]  J. Shanley,et al.  Mucosal immunization with a replication-deficient adenovirus vector expressing murine cytomegalovirus glycoprotein B induces mucosal and systemic immunity. , 2003, Vaccine.

[22]  R. K. Evans,et al.  Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene , 2003, Journal of Virology.

[23]  J. Prieto,et al.  Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. , 2002, Vaccine.

[24]  Z. Xiang,et al.  Novel, Chimpanzee Serotype 68-Based Adenoviral Vaccine Carrier for Induction of Antibodies to a Transgene Product , 2002, Journal of Virology.

[25]  Henryk Mach,et al.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.

[26]  C. Kedinger,et al.  Functional Analysis of Adenovirus Protein IX Identifies Domains Involved in Capsid Stability, Transcriptional Activity, and Nuclear Reorganization , 2001, Journal of Virology.

[27]  M. Dobbelstein,et al.  The Nuclear Export Signal within the E4orf6 Protein of Adenovirus Type 5 Supports Virus Replication and Cytoplasmic Accumulation of Viral mRNA , 2000, Journal of Virology.

[28]  A. van der Eb,et al.  New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. , 1998, Human gene therapy.

[29]  C. Kedinger,et al.  The product of the adenovirus intermediate gene IX is a transcriptional activator , 1997, Journal of virology.

[30]  B. Sugarman,et al.  Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. , 1997, Human gene therapy.

[31]  T. Dobner,et al.  Structural analysis of the adenovirus type 5 E1B 55-kilodalton-E4orf6 protein complex , 1997, Journal of virology.

[32]  A. Houweling,et al.  Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. , 1996, Human gene therapy.

[33]  K. Leppard,et al.  Constitutive episomal expression of polypeptide IX (pIX) in a 293-based cell line complements the deficiency of pIX mutant adenovirus type 5 , 1995, Journal of virology.

[34]  F. Graham,et al.  Packaging capacity and stability of human adenovirus type 5 vectors , 1993, Journal of virology.

[35]  L. Babiss,et al.  Promoter of the adenovirus polypeptide IX gene: similarity to E1B and inactivation by substitution of the simian virus 40 TATA element , 1991, Journal of virology.

[36]  F. Graham,et al.  Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes. , 1987, The EMBO journal.

[37]  T. Shenk,et al.  Adenovirus type 5 virions can be assembled in vivo in the absence of detectable polypeptide IX , 1981, Journal of virology.

[38]  J. Maizel,et al.  The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. , 1974, Virology.

[39]  H. Ertl,et al.  Induction of CD8+ T cells to an HIV-1 antigen upon oral immunization of mice with a simian E1-deleted adenoviral vector. , 2004, Vaccine.

[40]  T. Logtenberg,et al.  High‐Level Expression of Recombinant IgG in the Human Cell Line PER.C6 , 2003, Biotechnology progress.

[41]  Z. Xiang,et al.  Chimpanzee adenovirus CV-68 adapted as a gene delivery vector interacts with the coxsackievirus and adenovirus receptor. , 2002, The Journal of general virology.